XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.4

Trade and other receivables

6 Months Ended

Dec. 31, 2022

Text block [abstract]

Trade and other receivables

Note 8. Trade and other receivables

		Consolidated
		December 2022				June 2022
		$				$
GST refundable			69,093				51,353
Paxalisib Phase II clinical trial refund			631,876				—
			700,969				51,353
Deposit paid			40,159				39,622
			741,128				90,975

The Paxalisib Phase II clinical trial refund is the amount owing (US$428,096) from Labcorp Early Development Laboratories Inc. after their final reconciliation of trial costs. Funds were received on 3 January 2023.

X

- Definition

The disclosure of trade and other receivables. [Refer: Trade and other receivables]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 10
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Text block [abstract]

+ References

No definition available.

+ Details

Name:	kzia_TextBlockAbstract
Namespace Prefix:	kzia_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration